Browse > Article

Bioequivalence Evaluation of Two Cefquinome 2.5% Injectable Products in Piglets  

Song, In-Bae (Lab of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Chungnam National University)
Kim, Tae-Won (Lab of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Chungnam National University)
Lee, Hong-Gee (Lab of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Chungnam National University)
Kim, Myoung-Seok (Jeollanamdo Development Institute for Traditional Korean Medicine)
Hwang, Youn-Hwan (Korea Institute of Oriental Medicine)
Park, Byung-Kwon (Lab of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Chungnam National University)
Lim, Jong-Hwan (B&C Biopharm, Advanced Institutes of Convergence Technology)
Yun, Hyo-In (Lab of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Chungnam National University)
Publication Information
Journal of Veterinary Clinics / v.29, no.3, 2012 , pp. 233-236 More about this Journal
Abstract
Cefquinome, a fourth generation cephalosporin, has been solely used for veterinary medicine and has a broad antibacterial spectrum against gram-negatives and gram-positives being very stable to ${\beta}$-lactamases. This study was conducted to evaluate the bioequivalence of two cefquinome 2.5% products in piglets. Plasma cefquinome concentrations were analyzed by liquid chromatography-mass spectrometry (LC/MS). Mean maximum concentration ($C_{max}$) of test product ($Cequus^{(R)}$) and reference product ($Cobactan^{(R)}$) were $4.34{\pm}0.58$ and $4.22{\pm}0.47{\mu}g/mL$, and mean area under the concentration time curve ($AUC_{0{\rightarrow}{\infty}}$) values were $10.43{\pm}1.96$ and $10.25{\pm}2.98{\mu}g{\cdot}h/mL$, respectively. The 90% confidence intervals for the ratio of $C_{max}$ (0.941-1.115), and $AUC_{0{\rightarrow}{\infty}}$ (0.927-1.172) values for the test and reference products were within the acceptable bioequivalence limit of 0.80-1.25. It is concluded that two commercial cefquinome injectable solutions are bioequivalent in their extent of drug absorption in piglets.
Keywords
bioequivalence; cefquinome; LC/MS; pharmacokinetic;
Citations & Related Records
연도 인용수 순위
  • Reference
1 CVMP. Cefquinome summary report EMEA/MRL/005/95. London: European Agency for the Evaluation of Medicinal Products, 1995.
2 Ehinger AM, Schmidt H, Kietzmann M. Tissue distribution of cefquinome after intramammary and "systemic" administration in the isolated perfused bovine udder. Vet J 2006; 172: 147-153.   DOI   ScienceOn
3 El-Gendy AAM, Tohamy MA, Radi AM. Pharmacokinetic profile and some pharmaco- dynamic aspects of cefquinome in chickens. Beni-Suef Vet Med J 2009; 19: 33-37.
4 Grahnen A. Design of bioavailability studies. Pharm Int 1984; 5: 100-103.
5 Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Therapeut 1990; 28: 72-78.
6 Al-Taher AA. Pharmacokinetics of cefquinome in camels. J Anim Vet Adv 2010; 9: 848-852.   DOI
7 CVMP. Cefquinome (Extension to horses). Summary reprot (3) EMEA/MRL/888/03-FINAL. London: European Agency for the Evaluation of Medicinal Products, 2003.
8 Korea Animal, Plant and Fisheries Quarantine and Inspection Agency. In: The guideline of bioequivalence test for veterinary drugs. Korea: 2011; No. 2011-12.
9 Korea Animal, Plant and Fisheries Quarantine and Inspection Agency. In: The guideline of residue test for veterinary drugs. Korea: 2011; No. 2011-16.
10 Li XB, Wu WX, Su D, Wang ZJ, Jiang HY, Shen JZ. Pharmacokinetics and bioavailability of cefquinome in healthy piglets. J Vet Pharmacol Ther 2008; 31: 523-527.   DOI   ScienceOn
11 Limbert M, Isert D, Klesel N, Markus A, Seeger K, Seibert G, Schrinner E. Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 1991; 35: 14-19.   DOI   ScienceOn
12 Lui B, Zhang C, Zhang X, Yang S, Yu J, Sun J, Lui Y. Pharmacokinetics and bioavailability of cefquinome in crossbred wild boars. J Vet Pharmacol Therap 2012; doi:10.1111/j.1365-2885.2011.01360.x.
13 Rose M, Thomas V, Nordmann P. In vitro activity of third and fourth generation cephalosporins against E. coli strains expressing plasmid-encoded AmpC cephalosporinases. In: Risk Management for the Limitation of Antibiotic Resistance, Scientific Symposium. Federal Office of Consumer Protection and Food Safety, Berlin, Germany, 2004; 15-16.
14 Uney K, Altan F, Elmas M. Development and validation of an HPLC method for the determination of cefquinome in sheep plasma and its application to the pharmacokinetic study. Antimicrob Agents Chemother 2010; 55: 854-859.
15 Westlake WJ. Bioavailability and bioequivalence of pharmaceutical formulations. In: Biopharmaceutical Statistics for Drug Development, New York: Marcel Dekker. 1988: 329-352.
16 Yuan L, Sun J, Wang R, Sun L, Zhu L, Luo X, Fang B, Liu Y. Pharmacokinetics and bioavailability of cefquinome in healthy ducks. Am J Vet Res 2011; 72: 122-126.   DOI   ScienceOn